Compare KLTR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLTR | SGMT |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.4M | 238.7M |
| IPO Year | 2021 | 2023 |
| Metric | KLTR | SGMT |
|---|---|---|
| Price | $1.71 | $6.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.50 | ★ $29.71 |
| AVG Volume (30 Days) | 348.9K | ★ 626.9K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $1.36 | $1.73 |
| 52 Week High | $2.82 | $11.41 |
| Indicator | KLTR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 38.86 |
| Support Level | $1.64 | $5.80 |
| Resistance Level | $1.72 | $6.33 |
| Average True Range (ATR) | 0.09 | 0.42 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 63.46 | 21.46 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.